Back

Watch Compare

Turn Therapeutics Inc.

Data quality: 83%

TTRX

Nasdaq Manufacturing Chemicals

$3.50

$0.00 (0.00%)

Mkt Cap: 104.26 M

Price

$3.50

Mkt Cap

104.26 M

Day Range

$3.41 — $3.50

52-Week Range

$2.57 — $26.50

Volume

14,362

Open $3.50

50D / 200D Avg

$3.65

4.16% below

50D / 200D Avg

$4.01

12.77% below

Quick Summary

Key Takeaways

Negative free cash flow of -2.56 M

Growth

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Quality

Return on Equity

-68.15%

Below sector avg (-51.02%)

ROIC-75.15%

Net MarginN/A

Op. MarginN/A

Safety

Debt / Equity

N/A

Current Ratio1.43

Interest CoverageN/A

Valuation

PE (TTM)

-32.64

Below sector avg (-1.98)

P/B Ratio206.85

EV/EBITDAN/A

Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (44 peers)

Metric	Stock	Sector Median
P/E	-32.6	-2.0
P/B	206.9	5.1
ROE %	-68.2	-51.0
Net Margin %	—	-150.2
Rev Growth 5Y %	—	9.3
D/E	—	0.3

All Fundamental Metrics

Growth
Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	N/A	Net Income (TTM)	-3.19 M
ROE	-68.15%	ROA	-26.26%
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	-2.56 M
ROIC	-75.15%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	N/A	Current Ratio	1.43
Interest Coverage	N/A	Asset Turnover	N/A
Working Capital	985,486	Tangible Book Value	-400,866
Dividends
Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	-32.64	Forward P/E	N/A
P/B Ratio	206.85	P/S Ratio	N/A
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	-2.46%
Market Cap	104.26 M	Enterprise Value	103.74 M
Per Share
EPS (Diluted TTM)	-0.12	Revenue / Share	N/A
FCF / Share	-0.09	OCF / Share	-0.09
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A
Efficiency
CapEx / Revenue	N/A	FCF Conversion	80.24%
SBC-Adj. FCF	-2.98 M	Growth Momentum	N/A

Income Statement

Annual, most recent first

Metric	FY2025
Revenue	—
Net Income	-3.19 M
EPS (Diluted)	-0.12
Gross Profit	—
Operating Income	-5.86 M
EBITDA	—
R&D Expenses	265,570.0
SG&A Expenses	—
D&A	52,746.0
Interest Expense	—
Income Tax	—

Balance Sheet

Annual, most recent first

Metric	FY2025
Total Assets	12.16 M
Total Liabilities	7.48 M
Shareholders' Equity	4.69 M
Total Debt	—
Cash & Equivalents	4.03 M
Current Assets	5.20 M
Current Liabilities	6.00 M